Outcome Following Antidepressant Treatment on Possible Endo-Phenotypes for Major Depression
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00386841|
Recruitment Status : Completed
First Posted : October 12, 2006
Last Update Posted : June 30, 2009
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: Escitalopram Drug: Placebo||Phase 4|
The research in depression has for some years focused at the identification of endo-phenotypes. Endo-phenotypes are heritable biological or psychological markers, which are more commonly found in patients and their healthy relatives than in the general population.
Recent studies point at disturbed regulation of the hypothalamic-pituitary-adrenocortical (HPA) system as a possible endo-phenotype for depression.
The hypothesis of AGENDA are that endo-phenotypes are affected by treatment with antidepressants in healthy first degree relatives.
AGENDA is a four week randomized, placebo-controlled, double-blind trial in which first degree relatives of patients with the diagnosis of depression are randomised in to two groups, which are treated with either placebo or antidepressant medicine (Cipralex). We expect to include 80 healthy subjects, with the predisposition for depression, since one of their parents or siblings recently was treated for depression.
The subjects will be examined before and after four weeks of treatment by a thorough interview concerning psychiatric symptoms (SCAN), including depressive symptoms, personality, perceived stress and cognitive function. The effect of antidepressant on stress is measured with saliva-cortisol and by the response to the combined dexamethasone corticotropin-releasing (CRH) hormone test. Additionally, MR and PET scans of the 5-HT4 receptor function will be conducted before and after 4 weeks of treatment.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||Associations Between Gene-Polymorphisms, Endo-Phenotypes for Depression and Antidepressive Treatment (AGENDA)|
|Study Start Date :||April 2007|
|Actual Primary Completion Date :||June 2009|
|Actual Study Completion Date :||June 2009|
Active Comparator: A Escitalopram 10 mg
Escitalopram 10 mg
Escitalopram 10 mg p.o. per day
Other Name: cipralex
Placebo Comparator: Placebo
- Changes in the response on the combined dexamethasone corticotropin-releasing hormone test before and after 4 weeks treatment with escitalopram or placebo. [ Time Frame: 4-6 weeks ]
- Changes in scores before and after 4 weeks treatment with escitalopram or placebo on: Cognition [ Time Frame: 4-6 weeks ]
- Social function [ Time Frame: 4-6 weeks ]
- Neuroticism [ Time Frame: 4-6 weeks ]
- Subjective; sleep, pain, aggression, depression, anxiety, quality of life, perceived stress and side-effects [ Time Frame: 4-6 weeks ]
- Receptor status by PET-scans [ Time Frame: 4-6 weeks ]
- Inflammatory parameters [ Time Frame: 4-6 weeks ]
- Paraclinical measures [ Time Frame: 4-6 weeks ]
- MR and fMRI [ Time Frame: 4-6 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00386841
|Psychiatric Department of Rigshospitalet|
|Blegdamsvej 9, Copenhagen OE, Denmark, 2100|
|Study Director:||Lars V Kessing, DMSc||Psychiatric Department of Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen OE|